ResMed Inc.
ResMed Inc. (RMD) is a global medical‑technology company best known for devices that treat sleep apnoea, chronic obstructive pulmonary disease (COPD) and other respiratory conditions. It sells CPAP machines, masks, ventilators and a growing suite of cloud-connected software and services aimed at long‑term patient management. Revenue mixes device sales, consumables and recurring digital subscriptions — a model that can support predictable cash flow as the installed base and mask/consumable replacements continue. Key attractions for investors include an ageing population, steady demand for sleep solutions, and ResMed’s push into remote-monitoring and digital health. Risks include reimbursement changes, competition from other device makers, supply‑chain pressures and regulatory approvals; performance can vary and past results do not guarantee future returns. Market cap is about $39.1bn, making it a large-cap healthcare name. This is general educational information, not personalised advice — consider your personal circumstances and tolerance for volatility before investing.
Why It's Moving
ResMed's Q2 Earnings Beat and Margin Expansion Signal Momentum Despite Recent Insider Selling Concerns
- Q2 revenue of $1.423B grew 11% year-over-year with non-GAAP diluted EPS up 16% to $2.81, reflecting strong operational leverage and cost improvements from manufacturing and component efficiencies
- CEO Michael Farrell sold $1.25 million in shares through a pre-arranged plan, triggering a 2.6% single-day decline as investors weighed insider confidence signals alongside concerns about future prospects
- Baird downgraded its price target to $272 from $281 while maintaining a Neutral rating, though the stock has declined 18.4% from its August 2025 peak of $293.73, now trading around $230-240 per share
ResMed's Q2 Earnings Beat and Margin Expansion Signal Momentum Despite Recent Insider Selling Concerns
- Q2 revenue of $1.423B grew 11% year-over-year with non-GAAP diluted EPS up 16% to $2.81, reflecting strong operational leverage and cost improvements from manufacturing and component efficiencies
- CEO Michael Farrell sold $1.25 million in shares through a pre-arranged plan, triggering a 2.6% single-day decline as investors weighed insider confidence signals alongside concerns about future prospects
- Baird downgraded its price target to $272 from $281 while maintaining a Neutral rating, though the stock has declined 18.4% from its August 2025 peak of $293.73, now trading around $230-240 per share
When is the next earnings date for ResMed Inc. (RMD)?
ResMed's most recent earnings report was released on January 29, 2026 for Q2 fiscal 2026, which covered the quarter ended December 31, 2025. Based on the company's historical earnings schedule, the next earnings release for Q3 fiscal 2026 is typically expected in late April 2026, though an exact date has not yet been announced. Investors should monitor ResMed's investor relations website for the official announcement of the Q3 2026 earnings date and time.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying ResMed's stock, indicating expected growth towards a higher target price.
Financial Health
ResMed is performing well with strong revenue and cash flow, indicating good financial stability.
Dividend
ResMed's dividend yield of 0.92% is below average, which may not appeal to dividend-seeking investors. If you invested $1000 you would be paid $9.20 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring RMD
Wearable Health Stocks: Growth Potential vs Competition
Apple's recent FDA clearance for its Apple Watch hypertension feature marks a major step in wearable medical technology. This development opens up investment opportunities in the broader ecosystem of connected health devices and remote patient monitoring services.
Published: September 12, 2025
Explore BasketRest & Recharge
Tap into the booming wellness economy with companies revolutionizing how we sleep and relax. These carefully selected stocks represent innovative leaders in sleep technology, relaxation services, and wellness solutions that are responding to our growing desire for better rest and recovery.
Published: June 17, 2025
Explore BasketRest & Recovery
This carefully curated collection features companies at the forefront of sleep science and recovery technology. These stocks represent a growing market where innovation meets wellness, selected by professional analysts tracking the expanding health optimization trend.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring revenue model
ResMed’s mix of devices plus consumables and subscriptions can create steadier cash flows, though revenues still face reimbursement and demand risks.
Global patient base
An ageing population and rising diagnosis of sleep disorders support long-term demand, but regional regulation and payor policies can affect growth.
Connected‑care push
Investment in cloud platforms and remote monitoring could boost stickiness and services revenue, yet technology adoption and competition may vary.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
